Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity

Journal of Immunology

Volumn 160, Issue 2, 1998, Pages 643-651

  Morgan, David J ^a   Kreuwel, Huub T C ^a   Fleck, Shonna ^a   Levitsky, Hyam I ^b   Pardoll, Drew M ^b   Sherman, Linda A ^a,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPITOPE MAPPING; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; INFLUENZA VIRUS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; T LYMPHOCYTE ACTIVATION; VIRUS EXPRESSION;

ANIMALS; AUTOIMMUNITY; CELL DIVISION; EPITOPES, T-LYMPHOCYTE; GRAFT REJECTION; H-2 ANTIGENS; HEMAGGLUTININS; INFLUENZA A VIRUS; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0031963994     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Boon, T., J. C. Cerottini, B. van den Eynde, P. van der Bruggen, and A. van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
2. Ioannides, C. G., B. Fisk, D. Fan, W. E. Biddison, J. T. Wharton, and C. A. O'Brian. 1993. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell. Immunol. 151: 225.
3. Peoples, G. E., P. S. Goedegebuure, R. Smith, D. C. Linehan, I. Yoshino, and T. J. Eberlein. 1995. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA 92: 432.
4. Disis, M. L., J. W. Smith, A. E. Murphy, W. Chen, and M. A. Cheever. 1994. In vitro generation of human cytolytic T-cells specific for peptides derived from the Her-2/neu protooncogene protein. Cancer Res. 54:1071.
5. Theobald, M., J. Biggs, D. Dittmer, A. J. Levine, and L. A. Sherman. 1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92:11993.
6. Ropke, M., J. Hald, P. Guldberg, J. Zeuthen, L. Norgaard, L. Fugger, A. Svejgaard, S. van Der Burg, H. W. Nijman, C. J. M. Melief, and M. H. Claesson. 1996. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA 93:14704.
7. Lustgarten, J., M. Theobald, C. Labadie, D. LaFace, P. Peterson, M. L. Disis, A. Cheever, and L. A. Sherman. 1997. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum. Immunol. 52:109.
8. Brichard, V., A. van Pel, T. Wolfel, C. Wolfel, E. de Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489.
9. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
10. Coulie, P. G., V. Brichard, A. van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, and J. P. Szikora. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
11. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
12. Bakker, A. B. H., M. W. J. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005.
13. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689.
14. Nanda, N. K., and E. E. Sercarz. 1995. Induction of anti-self-immunity to cure cancer. Cell 82:13.
15. Houghton, A. N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1.
16. Golumbek, P., H. Levitsky, L. Jaffee, and D. M. Pardoll. 1994. The antitumor immune response as a problem of self-nonself discrimination: implications for immunotherapy. Immunol. Res. 12:183.
17. Cabaniols, J.-P., R. Cibotti, P. Kourilsky, K. Kosmatopoulos, and J. M. Kanellopoulos. 1994. Dose-dependent T cell tolerance to an immunodominant self peptide. Eur. J. Immunol. 24:1743.
18. Goverman, J., A. Woods, L. Larson, L. P. Weiner, L. Hood, and D. M. Zaller. 1993. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 72:551.
19. Von Herrath, M. G., J. Dockter, and M. B. A. Oldstone. 1994. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1:231.
20. Miller, J. F. A. P., and G. Morahan. 1992. Peripheral T cell tolerance. Annu. Rev. Immunol. 10:51.
21. Oehen, S. U., P. S. Ohashi, K. Burki, H. Hengartner, R. M. Zinkernagel, and P. Aichele. 1994. Escape of thymocytes and mature T cells from clonal deletion due to limiting toleragen expression levels. Cell. Immunol. 158:342.
22. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malissen, R. M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305.
23. Oldstone, M. B. A., M. Nerenberg, P. Southern, J. Price, and H. Lewicki. 1991. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65:319.
24. Poindexter, N. J., C. Landon, P. J. Whiteley, and J. A. Kapp. 1992. Comparison of the T cell receptors on insulin-specific hybridomas from insulin transgenic and nontransgenic mice. J. Immunol. 149:38.
25. Poplonski, L., B. Vukusic, S. Pawling, S. Clapoff, J. Roder, N. Hozumi, and J. Whither. 1996. Tolerance is overcome in beef insulin-transgenic mice by activation of low-affinity autoreactive T cells. Eur. J. Immunol. 26:601.
26. Whitely, P. J., N. J. Poindexter, C. Landon, and J. A. Kapp. 1990. A peripheral mechanism preserves self-tolerance to a secreted protein in transgenic mice. J. Immunol. 145:1376.
27. Yule, T. D., A. Bastin, and P. M. Allen. 1993. Hen egg-white lysozyme-specific T cells elicited in hen egg-white lysozyme-transgenic mice retain an imprint of self-tolerance. J. Immunol. 151:3057.
28. Kappler, J. W., N. Roehm, and P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273.
29. + thymocytes. Nature 333:742.
30. a-encoded antigens. Nature 332: 40.
31. Surh, C. D., and J. Sprent. 1994. T cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372:100.
32. Cibotti, R., J.-P. Cabaniols, C. Pannetier, C. Delarbre, I. Vergnon, J. M. Kanellopoulos, and P. Kourilsky. 1994. Public and private Vβ T cell receptor repertoires against hen egg white lysozyme (HEL) in non-transgenic versus HEL transgenic mice. J. Exp. Med. 180:861.
33. Roth, J., D. Dittmer, D. Rea, J. Tartaglia, E. Poaletti, and A. J. Levine. 1996. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor challenge. Proc. Natl. Acad. Sci. USA 93:4781.
34. Marchland, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascineli, A. Bourlond, R. Vanwijck, Y. Humblet, J.-L. Canon, C. Laurent, J.-M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jager, F. Brasseur, J. Herman, and P. G. Goulie. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63:883.
35. Jager, E., M. Ringhoffer, H. P. Dienes, M. Arand, J. Karbachi, D. Jager, C. Ilsemann, M. Hagedorn, F. Oesch, and A. Knuth. 1996. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 67:54.
36. Mayordomo, J. I., D. J. Loftus, H. Sakamoto, C. M. De Cesare, P. M. Appasamy, M. T. Lotze, W. J. Storkus, E. Appella, and A. B. DeLeo. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357.
37. + T cells. Eur. J. Immunol. 22:1013.
38. + cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157:978.
39. Murphy, G. P., and W. J. Hrushesky. 1973. A murine renal cell carcinoma. J. Natl. Cancer Inst. 50:1013.
40. Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290.
41. Antoniou, A., D. McCormick, D. Scott, H. Yeoman, P. Chandler, A. Mellor, and J. Dyson. 1996. T cell tolerance and activation to a transgene encoded tumor antigen. Eur. J. Immunol. 26:1094.
42. Huang, A. Y. C., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. I. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
43. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med 143:1283.
44. Jondal, M., R. Schirmbeck, and J. Reimann. 1996. MHC class I-restricted CTL responses to exogenous antigens. Immunity 5:295.
45. Cai, Z., and J. Sprent. 1996. Influence of antigen dose and co-stimulation on the primary response of CD8+ T cells in vitro. J. Exp. Med. 183:2247.
46. Kundig, T. M., A. Shahinian, K. Kawai, H.-W. Mittrucker, E. Sebzda, M. F. Bachmann, T. W. Mak, and P. S. Ohashi. 1996. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 5:41.
47. Bachmann, M. F., E. Sebzda, T. M. Kundig, A. Shahinian, D. E. Speiser, T. W. Mak, and P. S. Ohashi. 1996. T cell responses are governed by avidity and costimulatory thresholds. Eur. J. Immunol. 26:2017.
48. Bluestone, J. A. 1995. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555.
49. Green, J. M., P. J. Noel, A. I. Sperling, T. L. Walunas, G. S. Gray, J. A. Bluestone, and C. B. Thompson. 1994. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1:501.
50. Kundig, T. M., M. F. Bachmann, C. DiPaolo, J. J. L. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhlcke, P. S. Ohashi, H. Hengartner, and R. M. Zinkernagel. 1995. Fibroblasts as efficient antigen presenting cells in lymphoid organs. Science 268:1343.
51. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kündig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609.
52. Sercarz, E. E., P. V. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11:729.
53. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93:4102.
54. Speiser, D. E., D. Kyburz, U. Stuebi, H. Hengartner, and R. M. Zinkernagel. 1992. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. J. Immunol. 149:972.
55. Milner, J. 1984. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature 310:143.
56. Rogel, A., M. Popliker, C. G. Webb, and M. Oren. 1985. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell. Biol. 5:2851.
57. Terada, N., J. J. Lucas, and E. W. Gelfand. 1991. Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb), and p53 during cell cycle progression of normal human T cells. J. Immunol. 147:698.
58. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185:833.